A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer.
PURPOSE: Preclinical data have demonstrated that farnesyltransferaseinhibitors (FTIs) are radiation sensitizers in selected cell lines. The objective of this Phase I trial was to determine the maximally tolerated dose of the FTI L-778,123 in combination with radiotherapy in non-small cell lung canc...
Main Authors: | Hahn, S, Bernhard, E, Regine, W, Mohiuddin, M, Haller, D, Stevenson, J, Smith, D, Pramanik, B, Tepper, J, DeLaney, T, Kiel, K, Morrison, B, Deutsch, P, Muschel, R, Mckenna, W |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2002
|
Similar Items
-
A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer.
by: Martin, N, et al.
Published: (2004) -
A phase I trial of the farnesyltransferase and geranylgeranyltransferase-I inhibitor L-778,123 (L-778) and radiotherapy for locally advanced pancreatic cancer.
by: Martin, N, et al.
Published: (2004) -
Phase I trial of the farnesyl protein transferase (FPTASE) inhibitor L-778123 in combination with radiotherapy
by: Hahn, S, et al.
Published: (2000) -
Farnesyltransferase inhibitors as radiation sensitizers.
by: Mckenna, W, et al.
Published: (2002) -
Farnesyltransferase inhibitors.
by: Hahn, S, et al.
Published: (2001)